{"id":5337,"date":"2025-01-14T16:00:03","date_gmt":"2025-01-14T21:00:03","guid":{"rendered":"https:\/\/ahvmed.com\/?p=5337"},"modified":"2025-01-14T16:00:03","modified_gmt":"2025-01-14T21:00:03","slug":"polypill-treatment-for-heart-disease-offers-high-value-in-low-income-underserved-population","status":"publish","type":"post","link":"https:\/\/ahvmed.com\/?p=5337","title":{"rendered":"Polypill treatment for heart disease offers high value in low-income, underserved population"},"content":{"rendered":"
\n
\n
\n \"Polypill
\n <\/figure>\n<\/p><\/div>\n

Polypill treatment for cardiovascular disease prevention is of high value in a low-income, underserved population, according to research published in JAMA Cardiology<\/i>.<\/p>\n

Ciaran N. Kohli-Lynch, Ph.D., from the Feinberg School of Medicine at Northwestern University in Chicago, and colleagues simulated clinical and economic outcomes of the Southern Community Cohort Study (SCCS) Polypill Trial from a health care sector perspective, adopting a time horizon of 10 years. In the base case analysis, polypill<\/a> treatment was priced at $463 per year. An SCCS Polypill Trial-representative cohort of 100,000 individuals and all trial-eligible non-Hispanic Black adults was analyzed.<\/p>\n

The researchers found that polypill treatment was projected to yield a mean of 1,190 additional quality-adjusted life-years (QALYs) compared with usual care in the trial-representative cohort of 100,000 individuals, at a cost of about $10,152,000. The cost of polypill treatment was estimated at $8,560 per QALY gained compared with usual care, and had high value in 99% of simulations. Polypill treatment was estimated to be of high value and cost-saving when priced at $559 or less per year and $443 or less per year, respectively. Polypill treatment remained high value in almost all sensitivity analyses. Polypill treatment offered high value in a secondary analysis of 3,602,427 trial-eligible non-Hispanic Black U.S. adults, with an estimated cost of $13,400 per QALY gained.<\/p>\n

“In this economic evaluation<\/a>, using a computer simulation model<\/a>, we projected that the polypill would be high value in this population if priced based on its component medications ($463 per year) and may reduce income-related health disparities,” the authors write.<\/p>\n

\n

More information:<\/strong>
\n Ciaran N. Kohli-Lynch et al, Cost-Effectiveness of a Polypill for Cardiovascular Disease Prevention in an Underserved Population, JAMA Cardiology<\/i> (2025). DOI: 10.1001\/jamacardio.2024.4812<\/a>\n<\/p>\n

Clyde W. Yancy et al, Genius and the CVD Polypill\u2014A Step Toward Achieving Health Equity?, JAMA Cardiology<\/i> (2025). DOI: 10.1001\/jamacardio.2024.4820<\/a><\/p>\n<\/p><\/div>\n

\n 2025 HealthDay. All rights reserved.\n <\/p>\n

\n

Citation<\/strong>:
\n Polypill treatment for heart disease offers high value in low-income, underserved population (2025, January 13)
\n retrieved 14 January 2025
\n from https:\/\/medicalxpress.com\/news\/2025-01-polypill-treatment-heart-disease-high.html\n <\/p>\n

\n This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
\n part may be reproduced without the written permission. The content is provided for information purposes only.\n <\/p>\n<\/p><\/div><\/div>\n

Read More<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Polypill treatment for cardiovascular disease prevention is of high value in a low-income, underserved population, according to research published in JAMA Cardiology. Ciaran N. Kohli-Lynch, Ph.D., from the Feinberg School of Medicine at Northwestern University in Chicago, and colleagues simulated clinical and economic outcomes of the Southern Community Cohort Study (SCCS) Polypill Trial from a<\/p>\n","protected":false},"author":436,"featured_media":5338,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[53],"tags":[],"class_list":{"0":"post-5337","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medicalnewstoday_com"},"menu_order":0,"_links":{"self":[{"href":"https:\/\/ahvmed.com\/index.php?rest_route=\/wp\/v2\/posts\/5337","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ahvmed.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ahvmed.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ahvmed.com\/index.php?rest_route=\/wp\/v2\/users\/436"}],"replies":[{"embeddable":true,"href":"https:\/\/ahvmed.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5337"}],"version-history":[{"count":0,"href":"https:\/\/ahvmed.com\/index.php?rest_route=\/wp\/v2\/posts\/5337\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ahvmed.com\/index.php?rest_route=\/wp\/v2\/media\/5338"}],"wp:attachment":[{"href":"https:\/\/ahvmed.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5337"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ahvmed.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5337"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ahvmed.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5337"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}